Geneva–(business telegram)– Medimaps Group (www.medimaps group.com), a Swiss/global med-tech company specializing in imaging software for assessing bone health, today presented its Trabecular Bone Score (TBS) at RSNA 2002 ) announced a series of performances and events featuring software.
MediMap at its booth (#3955, AI Showcase – South Hall Level 3) will demonstrate how its TBS software, when combined with bone mineral density (BMD), provides important information on microarchitecture, which can aid in the diagnosis of osteoporosis, as well as There is a missing piece. Patient’s fracture risk. Reserve a private demonstration now on Book a Demo.
Lynn A. Kollmeier, MD, a practicing endocrinologist who has incorporated TBS into patient care protocols, will host the Innovation Showcase presentation: “Rethinking How to Diagnose Osteoporosis. Do You Have the Whole Picture?” 28-Nov, 11:30-11:45am CT on the AI Innovation Stage.
MediMaps will conduct an on-site survey to collect information from RSNA attendees regarding osteoporosis awareness and testing. A QR code in the MediMaps booth as well as its Innovation Showcase presentation provides access to the survey and real-time results.
providing a complete picture of bone health
TBS measurements combined with BMD may present a complete “bone-health” picture by adding information on bone composition to complement bone density. Within moments, Medimaps Group’s software, TBS Insight™, provides an easy-to-understand score for clinicians to quickly identify and classify patients’ fracture risk and implement a course of intervention. BMD tests alone miss 50% of patients who will eventually fracture, Incorporating TBS into osteoporosis screening has been shown to cut that number in half, with this simple $40 (USD) reimbursable test having the potential to save billions in fracture and osteoporosis care.
Medimaps CEO Prof. “Our proprietary and patented TBS technology is powered by a deep learning multi-layer approach, making it applicable to a broad spectrum of image modalities and resolutions beyond bone densitometry,” said Didier Hans. “TBS is demonstrating diagnostic accuracy for primary and secondary osteoporosis in women and men and the time it takes to result in sustained bone loss with effective treatment (with increasing TBS) or in the absence of effective treatment (with decreasing TBS) appears sensitive to changes with TBS. Basically see the ability to integrate and expand.
MediMaps will demonstrate how their technology integrates seamlessly into the process of care, using the same images obtained for BMD assessment, so patients are not exposed to additional radiation. They will also discuss how TBS:
Has achieved international recognition with over 900 peer-reviewed scientific publications;
Included in many guidelines and used by more than 30,000 physicians worldwide, including major health institutes;
Aligns with physicians’ existing clinical workflows;
Proven and Clear in 60+ countries;
is reimbursable in the US and some European countries; And
Radiologists may help to play an even bigger role in osteoporosis.
TBS Showcased by Partners Hologic and GE at RSNA 2022
Medimaps Group’s TBS integrated into Hologic and GE’s DXA Systems delivers the latest in densitometry technology, which facilitates complete fracture risk assessment and can capture an additional 30% of patients at risk of fracture. Learn more at both GE’s and Hologic’s booths or visit Medimaps Group’s booth (#3955, AI Showcase – South Hall Level 3).
Innovation Showcase Presentation (28-Nov, 11:30-11:45am CT): “Rethinking How to Diagnose Osteoporosis. Do You Have the Whole Picture?”
Join us in examining the findings of a recent survey of US radiologists’ perceptions of osteoporosis. 95% of radiologists surveyed underestimated the percentage of non-osteoporotic patients with fractures, and 75% underestimated that number by more than half. This presentation will also discuss how TBS – the key missing variable – when taken into account, can help reduce the likelihood of missing patients at fracture risk.
Lynn A. Kollmeier, MD, will host the presentation. Dr. Kolmeier is an endocrinologist specializing in osteoporosis, parathyroid, pituitary, adrenal, and thyroid conditions. She has been involved in patient care, research and community educational programs in Spokane, Washington. She received her medical degree from Stanford University School of Medicine and has been practicing for over 20 years.
Osteoporotic fractures occur every 3 seconds; Current diagnostics tell only half the picture – 50% of patients are at risk of missing, BMD measures bone volume but not bone microarchitecture quality. Today’s current techniques for diagnosing osteoporosis only measure BMD, which satisfies only half of the World Health Organization’s definition of osteoporosis. The full definition includes BMD and trabecular bone score.(1) Osteoporosis is a condition of primary concern among the aging patient population. Patients at risk for osteoporotic fractures often receive a BMD assessment, which measures only bone quantity, but not bone quality. Medimaps Group’s TBS Insight works with BMD to analyze bone microarchitecture as an assessment of bone quality.
About Medimaps Group
Medimaps Group’s medical imaging software applications provide healthcare solutions based on patented multi-purpose technology with artificial intelligence capabilities that fit seamlessly into the workflow for the benefit of the patient. TBS iNsight™ (Osteo) has been used for years in clinical practice around the world in the field of osteoporosis. It has become the new gold standard for bone texture assessment in routine clinical practice. TBS has achieved international recognition with over 900 peer-reviewed scientific publications and is included in numerous guidelines and is used by over 30,000 clinicians worldwide, including leading health institutions. Learn more at https://www.medimapsgroup.com/.
1. “Consensus Development Conference Diagnosis, Prophylaxis and Treatment of Osteoporosis.” Am J Med. 1993;94:646–650. DOI: 10.1016/0002-9343(93)90218-e.